| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
|
|
|
||||||
|
||||||||
Comparative Study |
Angelo Bianchi Bonomi Hemophilia Thrombosis Center, Department of Internal Medicine and Dermatology, IRCCS Maggiore Hospital and University of Milan, Italy. augusto.federici@unimi.it
BACKGROUND AND OBJECTIVES: The assay of ristocetin co-factor activity of von Willebrand factor (VWF:RCo) is used in the screening of patients with suspected von Willebrand's disease (VWD), the most frequent inherited bleeding disorder. A correct diagnosis of VWD relies on platelet agglutination tests that have a low accuracy within and between assays. A more accurate VWF:RCo assay would improve VWD diagnosis and classification. DESIGN AND METHODS: We describe here an ELISA method in which a recombinant fragment of the alpha-subunit of platelet glycoprotein Ib-IX-V complex (rGPIbalpha) is bound to an anti-GPIbalpha monoclonal antibody immobilized onto microtiter plate wells and which captures plasma VWF in the presence of ristocetin. The results obtained with this ELISA assay were compared blindly with values calculated from the agglutination test in normal subjects (n=60) and in type 1 (n=8), type 2A (n=16), type 2B (n=13), type 2M (n=17) or type 2M Vicenza (n=8) VWD patients which were characterized by low VWF levels. RESULTS: The two assays gave similar results in both normal subjects and VWD patients (r=0.93), but the ELISA test showed higher sensitivity (0.1 versus 6.25 U/dL). The repeatability and reproducibility gave coefficients of variation of 9% and 10%, respectively, for the ELISA, as compared to 14% and 15% for the agglutination test. INTERPRETATION AND CONCLUSIONS: This ELISA assay can be useful in the identification and classification of VWD patients in that it may provide a more accurate distinction between type 2 with abnormal VWF function and type 1 with a low plasma VWF concentration.
This article has been cited by other articles:
|
|
 |
|
  S. Giannini, A. M. Mezzasoma, M. Leone, and P. Gresele Laboratory diagnosis and monitoring of desmopressin treatment of von Willebrand's disease by flow cytometry Haematologica, December 1, 2007; 92(12): 1647 - 1654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Pinol, M. Sales, M. Costa, A. Tosetto, M. T. Canciani, and A. B. Federici Evaluation of a new turbidimetric assay for von Willebrand factor activity useful in the general screening of von Willebrand disease Haematologica, May 1, 2007; 92(5): 712 - 713. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Goodeve, J. Eikenboom, G. Castaman, F. Rodeghiero, A. B. Federici, J. Batlle, D. Meyer, C. Mazurier, J. Goudemand, R. Schneppenheim, et al. Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD) Blood, January 1, 2007; 109(1): 112 - 121. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. A. Hassenpflug, U. Budde, T. Obser, D. Angerhaus, E. Drewke, S. Schneppenheim, and R. Schneppenheim Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis Blood, March 15, 2006; 107(6): 2339 - 2345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Baronciani, A. B. Federici, M. Beretta, G. Cozzi, M. T. Canciani, and P. M. Mannucci Biochemical Characterization of Recombinant Von Willebrand Factor (VWF) with a Type 2B Mutation (P1337L) Coexpressed with a Type 1 VWF Defect (C275R): A Complex Molecular Defect in a Patient Previously Diagnosed with Type 2A Von Willebrand Disease (VWD). Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 1025 - 1025. [Abstract]
|
|
| HOME | HELP | FEEDBACK | TABLE OF CONTENTS | ARCHIVE | SUBSCRIPTIONS |
